Psoriatic disease—which includes psoriasis, psoriatic arthritis (PsA), and the host of comorbidities that accompany them—carries a disproportionate cardiovascular (CV) burden, with excess major adverse CV events and CV mortality that scale with inflammatory severity. This has reframed psoriatic disease as a systemic condition in which immune activation, metabolic stress, and vascular injury converge [1]. Within this cardio–metabolic–inflammatory triad, hyperuricemia (HU) and gout are over-represented. Compared to the general population, patients with psoriasis have more than double the risk of developing HU, while patients with PsA can quadruple that incidence [2, 3]. The coexistence of PsA and gout, referred to as “Psout”, represents a distinct clinical phenotype. Although formal epidemiological data are still limited, current studies suggest that PsA patients have up to a five-fold increased risk of gout, supporting the clinical relevance of this overlapping phenotype, which complicates the management of both conditions [3]. Patients with Psout face increased difficulty in controlling urate levels due to the chronic inflammation associated with PsA, requiring integrated management strategies that target both inflammation and HU [3]. Despite robust associations, causality remains unsettled. Large outcome trials of urate-lowering therapy (ULT) outside the psoriatic setting have not shown CV benefit (e.g., ALL-HEART with high-dose allopurinol was neutral), and febuxostat appears cardiovascularly non-inferior to allopurinol in gout (FAST), despite a prior mortality signal in CARES (Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout) [4–6].

This editorial aims to stimulate reflection and promote an integrated, paradigm-shifting perspective on how HU, obesity, and psoriatic inflammation interconnect and should be jointly addressed. As this is a narrative editorial, causal inference should be interpreted cautiously, and the associations discussed here should be viewed as hypothesis-generating rather than definitive.

Psoriatic inflammation—dominated by IL‑23/IL‑17 and TNF‑α—amplifies endothelial activation (↑ VCAM‑1), oxidative stress, and NETosis, priming the arterial wall for atherogenesis. Uric acid adds a second pro‑inflammatory layer: crystal‑independent xanthine oxidase-derived ROS reduces nitric oxide bioavailability, while NLRP3‑inflammasome signaling increases IL‑1β/IL‑18, bridging innate immunity and vascular inflammation. Obesity/metabolic dysfunction closes the loop via adipokines (leptin, resistin, IL‑6, TNF‑α), non-alcoholic fatty liver disease (NAFLD), and insulin resistance—states that both raise serum uric acid (SUA) (overproduction/under‑excretion) and intensify psoriatic inflammation. In PsA, SUA correlates with subclinical atherosclerosis and endothelial dysfunction, though confounding by adiposity remains a consideration [3]. Table 1 summarizes these shared pathways.

However, as mentioned above, the relationship between uricemia and CV risk is far from linear, and causality is still debated. For example, the results of Mendelian randomization studies regarding this relationship outside of psoriatic disease are heterogeneous [2]; large-scale clinical trials on uricemia have either failed to show positive results in terms of CV protection (ALL-HEART) or have focused on safety (FAST, CARES) rather than benefits [4–6]. In contrast, anti-obesity therapies focus on the common root cause—adiposity—achieving weight loss, reduction of systemic inflammation, and modest reductions in systemic adiposity in diabetes/obesity cohorts. This, when applied to patients with HU, psoriatic disease, and metabolic conditions, could lay the groundwork for new therapeutic paradigms [3].

If urate sits within a broader immunometabolic web, therapies that reduce adiposity and cool systemic inflammation should help on several fronts—potentially including uric acid. Outside psoriatic disease, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) consistently induce meaningful weight loss and show modest reductions in SUA [7, 8]. Post‑hoc analyses demonstrate increased renal urate clearance and progressive SUA lowering with GLP-1 exposure [8]. A systematic review/meta‑analysis concluded that GLP-1 RAs reduce SUA modestly, with heterogeneity and small absolute effects [7]. Therefore, reductions in SUA with GLP-1-based therapies remain modest, and their clinical implications in PsA or psoriasis populations should be regarded as exploratory.

In psoriatic disease, early data are encouraging for skin and systemic inflammation, though urate endpoints are mostly absent. An open‑label randomized study of semaglutide in obese psoriasis patients with type 2 diabetes reported improvements in PASI, IL‑6/CRP, LDL, and body weight, but did not specify SUA/HU outcomes [9]. The integrated strategy is now on trial in PsA: TOGETHER‑PsA (ClinicalTrials.gov. NCT06588296) evaluates ixekizumab plus tirzepatide versus ixekizumab alone in adults with PsA and obesity/overweight—precisely the dual hit (inflammation + adiposity) envisioned, albeit without public urate endpoints. Therefore, for psoriatic patients with obesity and HU/gout, adding a GLP‑1/GIP‑based anti‑obesity therapy can be justified to address weight and inflammation while likely nudging SUA in the right direction, but gout still warrants guideline‑directed ULT [9, 10].

The management of HU and gout in psoriatic disease should be approached holistically, considering the interconnected nature of inflammation, obesity, and metabolic dysfunction. The main objectives are to optimize CV risk, control systemic inflammation, and reduce uric acid in patients who are at high risk of gout or CV events [3, 7, 9, 10]. This approach could be summarized as shown in Table 2.

The intention of this editorial is not only to summarize current evidence but also to encourage a more unified immunometabolic framework for clinical decision-making. Psoriatic disease exemplifies an immunometabolic disorder in which HU, obesity, and inflammation form a self‑reinforcing triad that accelerates atherosclerosis. Epidemiology and imaging link SUA with adverse vascular phenotypes in PsA, yet large trials of ULT have not delivered CV benefit outside gout. The credible path to impact is to treat the network: suppress psoriatic inflammation, debulk adiposity, and manage classical risk factors. GLP‑1/GIP‑based anti‑obesity pharmacotherapy may reshape care—improving weight and inflammatory markers and plausibly nudging urate—while gout, when present, continues to require guideline‑directed ULT.

Priorities include: (i) PsA/psoriasis cohorts with serial SUA and vascular imaging; (ii) randomized studies that co‑target inflammation (e.g., anti‑IL‑17/23) and adiposity (GLP‑1/GIP), with prespecified urate and vascular endpoints; (iii) Mendelian randomization focused on psoriatic populations; and (iv) real‑world registries capturing weight trajectories, SUA, flares, and CV events under modern anti‑obesity therapy.